CD274 and non-small cell lung carcinoma: Nivolumab later received FDA approval on 4 March 2015 for patients with squamous non-small-cell lung cancer (NSCLC) who progressed after platinum-doublet chemotherapy based on the result of the CheckMate-017 trial, with better ORR as well as survival benefit regardless of the PDL-1 expression level [37] (Category 1).